GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Cyclically Adjusted PB Ratio

Macrogenics (Macrogenics) Cyclically Adjusted PB Ratio : 2.20 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Macrogenics's current share price is $14.82. Macrogenics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $6.75. Macrogenics's Cyclically Adjusted PB Ratio for today is 2.20.

The historical rank and industry rank for Macrogenics's Cyclically Adjusted PB Ratio or its related term are showing as below:

MGNX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.36   Med: 0.94   Max: 2.82
Current: 2.16

During the past years, Macrogenics's highest Cyclically Adjusted PB Ratio was 2.82. The lowest was 0.36. And the median was 0.94.

MGNX's Cyclically Adjusted PB Ratio is ranked worse than
57.72% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs MGNX: 2.16

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Macrogenics's adjusted book value per share data for the three months ended in Dec. 2023 was $2.459. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.75 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Macrogenics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Macrogenics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Cyclically Adjusted PB Ratio Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.60 1.03 1.42

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.10 0.80 0.68 1.42

Competitive Comparison of Macrogenics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Macrogenics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's Cyclically Adjusted PB Ratio falls into.



Macrogenics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Macrogenics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.82/6.75
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Macrogenics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.459/129.4194*129.4194
=2.459

Current CPI (Dec. 2023) = 129.4194.

Macrogenics Quarterly Data

Book Value per Share CPI Adj_Book
201403 5.572 99.695 7.233
201406 5.121 100.560 6.591
201409 5.008 100.428 6.454
201412 4.332 99.070 5.659
201503 7.693 99.621 9.994
201506 7.027 100.684 9.033
201509 9.908 100.392 12.773
201512 9.123 99.792 11.831
201603 8.288 100.470 10.676
201606 9.511 101.688 12.105
201609 8.620 101.861 10.952
201612 7.707 101.863 9.792
201703 6.708 102.862 8.440
201706 6.307 103.349 7.898
201709 5.148 104.136 6.398
201712 8.118 104.011 10.101
201803 6.679 105.290 8.210
201806 7.389 106.317 8.995
201809 6.690 106.507 8.129
201812 5.735 105.998 7.002
201903 6.569 107.251 7.927
201906 6.022 108.070 7.212
201909 5.217 108.329 6.233
201912 4.711 108.420 5.623
202003 3.879 108.902 4.610
202006 4.643 108.767 5.525
202009 5.191 109.815 6.118
202012 5.261 109.897 6.196
202103 5.841 111.754 6.764
202106 5.306 114.631 5.990
202109 4.758 115.734 5.321
202112 3.908 117.630 4.300
202203 2.906 121.301 3.100
202206 2.318 125.017 2.400
202209 2.001 125.227 2.068
202212 2.302 125.222 2.379
202303 1.767 127.348 1.796
202306 2.770 128.729 2.785
202309 3.127 129.860 3.116
202312 2.459 129.419 2.459

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Macrogenics  (NAS:MGNX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Macrogenics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Macrogenics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Industry
Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949